Combination Vaccines of Fasciola gigantica Saposin-like Protein-2 and Leucine Aminopeptidase
Issued Date
2023-07-01
Resource Type
eISSN
24146366
Scopus ID
2-s2.0-85166421585
Journal Title
Tropical Medicine and Infectious Disease
Volume
8
Issue
7
Rights Holder(s)
SCOPUS
Bibliographic Citation
Tropical Medicine and Infectious Disease Vol.8 No.7 (2023)
Suggested Citation
Changklungmoa N., Cheukamud W., Jaikua W., Meemon K., Sobhon P., Kueakhai P. Combination Vaccines of Fasciola gigantica Saposin-like Protein-2 and Leucine Aminopeptidase. Tropical Medicine and Infectious Disease Vol.8 No.7 (2023). doi:10.3390/tropicalmed8070334 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/88282
Title
Combination Vaccines of Fasciola gigantica Saposin-like Protein-2 and Leucine Aminopeptidase
Author's Affiliation
Other Contributor(s)
Abstract
Saposin-like protein-2 (SAP-2) and leucine aminopeptidase (LAP) are major proteins involved in the digestive process of Fasciola gigantica (Fg). Both SAP-2 and LAP are highly expressed in F. gigantica; therefore, they could be vaccine candidates for fasciolosis. The aims of this study are (1) to observe the tissue expression of F. gigantica SAP-2 (FgSAP-2) and F. gigantica LAP (FgLAP) in F. gigantica by indirect immunofluorescence technique under confocal microscopy and (2) to test the vaccine potentials of individual and combined recombinant (r) FgSAP-2 and rFgLAP against F. gigantica in Imprinting Control Region (ICR) mice (n = 10 per group). By indirect immunofluorescence-confocal microscopy, FgSAP-2 and FgLAP were localized in the caecal epithelium but at different sites: FgSAP-2 appeared in small granules that are distributed in the middle and lower parts of the cytoplasm of epithelial cells, while FgLAP appeared as a line or zone in the apical cytoplasm of caecal epithelial cells. For vaccine testing, the percent protection of combined rFgSAP-2 and rFgLAP vaccines against F. gigantica was at 80.7 to 81.4% when compared with aluminum hydroxide (alum) adjuvant and unimmunized controls, respectively. The levels of IgG1 and IgG2a in the sera were significantly increased in single and combine vaccinated groups compared with the control groups. Vaccinated mice showed reduced liver damage when compared with control groups. This study indicates that the combined rFgSAP-2 and rFgLAP vaccine had a higher vaccine potential than a single vaccine. These results support the further testing and application of this combined vaccine against F. gigantica infection in farmed livestock animals.